NDC 50242-007

Enspryng

Satralizumab

Enspryng is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech Inc.. The primary component is Satralizumab.

• Product ID: 50242-007_29c34015-d4bb-4175-b9ff-d0f566d0bb9b
• NDC: 50242-007
• Product Type: Human Prescription Drug
• Proprietary Name: Enspryng
• Generic Name: Satralizumab
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2020-08-14
• Marketing Category: BLA / BLA
• Application Number: BLA761149
• Labeler Name: Genentech Inc.
• Substance Name: SATRALIZUMAB
• Active Ingredient Strength: 120 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 50242-007-01

1 SYRINGE, PLASTIC in 1 CARTON (50242-007-01) > 1 mL in 1 SYRINGE, PLASTIC

• Marketing Start Date: 2020-08-14
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details